Triple test
Triple test
The Triple test (pronounced: /ˈtrɪpəl tɛst/), also known as the Multiple Marker Screening or the AFP Plus is a prenatal screening procedure used to determine the likelihood of certain genetic disorders in a developing fetus.
Etymology
The term "Triple test" is derived from the fact that the test involves the analysis of three specific substances in the mother's blood: Alpha-fetoprotein (AFP), Human chorionic gonadotropin (hCG), and Unconjugated estriol (uE3).
Procedure
The Triple test is typically performed between the 15th and 20th weeks of pregnancy. It involves a blood draw from the mother, which is then analyzed for levels of AFP, hCG, and uE3. The results of this test, along with the mother's age and other factors, are used to calculate the risk of the fetus having certain genetic disorders, such as Down syndrome and Edwards syndrome.
Related Terms
- Alpha-fetoprotein (AFP): A protein produced by the fetus. High levels can indicate neural tube defects, while low levels can suggest chromosomal disorders.
- Human chorionic gonadotropin (hCG): A hormone produced by the placenta. Abnormal levels can indicate potential genetic disorders.
- Unconjugated estriol (uE3): A hormone produced by the fetus and the placenta. Low levels can suggest a risk of certain genetic disorders.
- Down syndrome: A genetic disorder caused by the presence of an extra chromosome 21.
- Edwards syndrome: A genetic disorder caused by the presence of an extra chromosome 18.
External links
- Medical encyclopedia article on Triple test
- Wikipedia's article - Triple test
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski